Anti-Hypertensive Drugs - G7

The projected revenue for the Anti-Hypertensive Drugs market in 2024 is estimated to be US$15.92bn.
It is expected to grow at an annual growth rate of -0.41% from 2024 to 2028, resulting in a market volume of US$15.66bn by 2028.
Among the G7 countries, United States is anticipated to generate the highest revenue in the market, reaching US$12,290.00m in 2024.
In the United States, the trend in the anti-hypertensive drugs market is a shift towards more personalized and targeted treatments.

Key regions: Germany, United States, France, China, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Hypertensive Drugs in G7 countries has been on the rise in recent years due to various reasons.

Customer preferences: The increasing prevalence of hypertension among the aging population and the sedentary lifestyle of the younger generation has led to a surge in demand for Anti-Hypertensive Drugs. Patients are also increasingly preferring combination drugs to single-ingredient medications, as they provide better efficacy and compliance.

Trends in the market: In the United States, the Anti-Hypertensive Drugs market is dominated by branded drugs, while the market in Japan is dominated by generics. In Europe, the market is highly fragmented with a mix of branded and generic drugs. However, the trend towards generic drugs is increasing due to the cost-effectiveness and the expiration of patents of branded drugs.

Local special circumstances: In France, the government has implemented measures to encourage the use of generic drugs to reduce healthcare costs. In the UK, the National Institute for Health and Care Excellence (NICE) has issued guidelines to promote the use of combination drugs over single-ingredient medications. In Germany, the market is highly regulated, and the government sets the prices for drugs, which has led to a decrease in the profitability of the pharmaceutical industry.

Underlying macroeconomic factors: The aging population in G7 countries is a significant factor driving the demand for Anti-Hypertensive Drugs. The sedentary lifestyle of the younger generation, coupled with unhealthy eating habits, has also contributed to the rise in hypertension cases. The increasing healthcare expenditure and the government's efforts to reduce healthcare costs have also influenced the Anti-Hypertensive Drugs market. The expiration of patents of branded drugs and the increasing trend towards generic drugs have also impacted the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.